Abstract
Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.
【초록키워드】 SARS-CoV-2, IgG, Efficacy, Vaccine, COVID-19 vaccine, vaccine doses, Immunity, antibody, Antibody Response, Infection, Sex, SARS-CoV2 infection, SARS-CoV-2 vaccine, Protein, S-RBD, response, female, age, respiratory, Anti-spike, antibody level, Immunological response, dose, Trigger, Support, Steady state, SNIBE, recipients, individual, domain, naïve, doses, decrease, males, independent, immunosurveillance, evaluate, induce, reactivity, the vaccine, healthy individual, baseline, IgG level, indirect chemiluminescence immunoassay, 【제목키워드】 BNT162b2 vaccine, anti-SARS-CoV-2, IgG antibody, S-RBD, longitudinal, Analysis, dose,